WO2002074279A2 - Formulation for treating body odour - Google Patents
Formulation for treating body odour Download PDFInfo
- Publication number
- WO2002074279A2 WO2002074279A2 PCT/IB2002/000771 IB0200771W WO02074279A2 WO 2002074279 A2 WO2002074279 A2 WO 2002074279A2 IB 0200771 W IB0200771 W IB 0200771W WO 02074279 A2 WO02074279 A2 WO 02074279A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- weight
- hexamine
- zinc oxide
- powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
Definitions
- THIS invention relates to a formulation for treating body odour, in particular for treating foot odour.
- a formulation for treating body odour, in particular foot odour comprising a combination of hexamine and zinc oxide or pharmaceutically acceptable salts thereof, typically formulated in solution, alone or in combination with one or more pharmaceutically acceptable excipients and/or carriers.
- An aqueous formulation preferably comprises 0,5 to 10% hexamine by weight of the formulation and 0,5 to 2% zinc oxide by weight of the formulation.
- the formulation preferably comprises calcium carbonate, talcum, glycerine (glycerol) and distilled water.
- the invention also covers a powder formulation for treating body odour, in particular foot odour, the formulation comprising a combination of hexamine and zinc oxide or pharmaceutically acceptable salts thereof, typically formulated in solution, alone or in combination with one or more pharmaceutically acceptable excipients and/or carriers.
- the powder can be applied to a person's skin in an affected area by sprinkling, or rubbing.
- the hexamine powder may be present in an amount of 30% to 50%, preferably 40% by weight of the composition.
- Zinc oxide, micronised talc and calcium carbonate are each present in an amount of 10% to 30%, preferably 20% by weight of the composition.
- the invention extends to the use of a combination of hexamine and zinc oxide in a method of making a medicament for treating body odour, in particular foot odour, and also to the use of this combination in the treatment of body odour, particularly foot odour.
- the topical formulation of the invention for treating body odour, in particular foot odour comprises a combination of hexamine and zinc oxide, or pharmaceutically acceptable salts thereof, alone or in combination with pharmaceutically acceptable excipients or carriers.
- the formulation is preferably provided as an aqueous solution, which can be applied to a person's skin in the affected area by way of spraying, coating or any other appropriate form.
- the hexamine and zinc oxide are both added to the aqueous solution in powder form, typically in an amount of 0,5% to 10% hexamine powder by weight of the formulation, and 0,5% to 2% by weight of the formulation zinc oxide powder.
- the hexamine powder is present in an amount of 2% to 4% by weight and zinc oxide powder in an amount of 1% to 2% by weight.
- the additional components in the preferred aqueous formulation of the invention include calcium carbonate, preferably in powder form, talcum, preferably pharmaceutical grade talcum powder, glycerine, (glycerol), preferably in liquid form, and the remainder distilled water. These additional components are preferably provided in amounts of 0,5 to 2% by weight calcium carbonate powder, 0,5 to 2% by weight talcum powder, 1 to 10% by weight glycerine liquid, and 90 to 99% by weight distilled water, respectively.
- the formulation may, however, be provided as a powder which can be applied to a person's skin in an affected area by sprinkling, or rubbing.
- hexamine powder is present in an amount of 30% to 50%, preferably 40% by weight of the composition.
- Zinc oxide, micronised talc and calcium carbonate are each present in an amount of 10% to 30%, preferably 20% by weight of the composition.
- a 100* batch topical treatment aqueous formulation of the invention can be formulated from the following components.
- 80* of water is placed into a mixing tank. 4kg of hexamine powder, 2kg of zinc oxide, 2kg of talc powder and 2kg calcium carbonate are added to the water in the mixing tank, with continuous mixing at a low speed. The hexamine dissolves into the water and the zinc oxide, talc powder and calcium carbonate form a suspension in the water. The 8J5kg glycerine is then added to the suspension while continuously mixing. Thereafter, the mixer is stopped and an additional 1 ,25* of purified water is added to make up the 100* batch formulation.
- the batch may then be decanted into suitable containers for application and sale, for example 30ml containers.
- suitable containers for application and sale, for example 30ml containers.
- the zinc oxide powder, calcium carbonate and talcum powder may settle to the bottom of the container, these ingredients are very easy to re-suspended by merely shaking the container before use.
- the container is preferably a plastic spray pump.
- Tests were carried out on 5 individuals who were afflicted with foot odour problems. A solution as formulated above was applied to the affected areas for three consecutive nights after bathing or just before bedtime. The individuals' shoes were also treated. All of the patients reported relief by the third application which relief persisted for at least six months after treatment.
- a 10kg batch topical treatment powder formulation of the invention can be formulated from the following components:
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002238803A AU2002238803A1 (en) | 2001-03-15 | 2002-03-15 | Formulation for treating body odour |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200102163 | 2001-03-15 | ||
ZA2001/2163 | 2001-03-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002074279A2 true WO2002074279A2 (en) | 2002-09-26 |
WO2002074279A3 WO2002074279A3 (en) | 2002-12-12 |
Family
ID=25589101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/000771 WO2002074279A2 (en) | 2001-03-15 | 2002-03-15 | Formulation for treating body odour |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002238803A1 (en) |
WO (1) | WO2002074279A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007096757A2 (en) * | 2006-02-23 | 2007-08-30 | Squilset Di Lovato Mariagrazia E Squillace Giuseppe S.N.C. | Tampon for medical use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1525971A (en) * | 1975-02-27 | 1978-09-27 | Hlavin L | Deodorant composition |
FR2443838A1 (en) * | 1978-12-11 | 1980-07-11 | Simovic Rastko | Skin cream to reduce perspiration of feet - contg. urotropin, glycerine, zinc oxide and talc |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2142757B1 (en) * | 1998-04-23 | 2001-04-01 | Quimversion S L | COMPOSITION IN THE FORM OF ADEQUATE EMULSION FOR THE TREATMENT OF HYPERHYDROSIS AND / OR PLANTAR BROMHIDROSIS |
-
2002
- 2002-03-15 AU AU2002238803A patent/AU2002238803A1/en not_active Abandoned
- 2002-03-15 WO PCT/IB2002/000771 patent/WO2002074279A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1525971A (en) * | 1975-02-27 | 1978-09-27 | Hlavin L | Deodorant composition |
FR2443838A1 (en) * | 1978-12-11 | 1980-07-11 | Simovic Rastko | Skin cream to reduce perspiration of feet - contg. urotropin, glycerine, zinc oxide and talc |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007096757A2 (en) * | 2006-02-23 | 2007-08-30 | Squilset Di Lovato Mariagrazia E Squillace Giuseppe S.N.C. | Tampon for medical use |
WO2007096757A3 (en) * | 2006-02-23 | 2008-07-10 | Squilset Di Lovato Mariagrazia | Tampon for medical use |
Also Published As
Publication number | Publication date |
---|---|
WO2002074279A3 (en) | 2002-12-12 |
AU2002238803A1 (en) | 2002-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5137718A (en) | Infection fighting composition for topical application | |
JPS62242618A (en) | Mercury-containing-antiseptic stabilized ophthalmic remedy | |
WO2008047680A1 (en) | External preparation for skin | |
JP2001131026A (en) | Cosmetic for scalp and hair | |
US4054649A (en) | Therapeutic compositions and the treatment of lesions of connective tissue | |
JP2011088930A (en) | Carbon dioxide percutaneous and transmucosal absorption composition | |
US20080145461A1 (en) | Formulation and method of making a topical pain relief composition | |
US5886038A (en) | Composition and method for treatment of psoriasis | |
WO2002074279A2 (en) | Formulation for treating body odour | |
JPH069391A (en) | Hyaluronidase activity inhibitor | |
AU768917B2 (en) | Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues | |
KR101874830B1 (en) | Antibacterial Cosmetics Composition | |
JPH11500730A (en) | Topical treatment of scar tissue and associated tissue response to trauma | |
JP3537671B2 (en) | Lipolysis accelerator and skin cosmetic for slimming | |
JP2000212090A (en) | Skin-modifying agent | |
JP3524169B2 (en) | Skin cosmetics for acne improvement | |
JP2020158493A (en) | Water-in-oil type (w/o type) cream containing panthenol | |
JP3675637B2 (en) | Composition for external use | |
JP3827259B2 (en) | Keratinization promoter | |
US20220362348A1 (en) | Lactoferrin, derived peptide thereof and method thereof for inhibiting and/or alleviating lipid synthesis | |
US11780883B2 (en) | Derived peptide of lactoferrin and method thereof for promoting and/or increasing lipid synthesis | |
US2697060A (en) | Emulsion of the essential oil derived from the western sagebrush | |
CN1320897C (en) | Filming aerosol for treating tinea coporis, tinea manuum and tinea pedis | |
JPS61207326A (en) | Skin treating composition | |
JP2001131025A (en) | Cosmetic for scalp and hair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |